Triple-negative breast cancer treatment options for unresectable locally advanced or metastatic disease expanded significantly when regulatory authorities approved pembrolizumab combined with chemotherapy, according to clinical trial data published in the New England Journal of Medicine. This immunotherapy approach targets programmed death ligand 1 (PD-L1) positive tumors, offering a new therapeutic pathway for patients facing aggressive cancer subtypes that lack estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) expression.
Clinical Trial Evidence and Survival Outcomes
The approval of pembrolizumab for triple-negative breast cancer (TNBC) stems from the pivotal Phase 3 KEYNOTE-355 clinical trial, as reported by the U.S. Food and Drug Administration. Researchers evaluated 847 patients with previously untreated, locally recurrent unresectable or metastatic TNBC. Participants received either pembrolizumab plus chemotherapy or a placebo plus chemotherapy. According to data released by trial investigators, patients whose tumors expressed PD-L1 with a combined positive score (CPS) of 10 or greater experienced a statistically significant improvement in progression-free survival when treated with the immunotherapy regimen.
Median progression-free survival reached 9.7 months in the pembrolizumab-plus-chemotherapy arm compared to 5.6 months in the control arm for patients with a CPS of 10 or higher, according to findings detailed by the European Society for Medical Oncology. This improvement demonstrated that adding immunotherapy to standard chemotherapy regimens delays disease progression in this specific patient population.
Understanding PD-L1 Biomarkers in TNBC
Biomarker testing plays a critical role in determining treatment eligibility for advanced TNBC. According to guidelines from the American Society of Clinical Oncology, pathologists assess PD-L1 expression using the 22C3 pharmDx assay. The combined positive score calculates the percentage of PD-L1-expressing tumor cells, lymphocytes, and macrophages relative to the total number of viable tumor cells. Identifying patients with a CPS of 10 or greater ensures that immunotherapy is directed toward individuals most likely to derive clinical benefit from checkpoint inhibition.
Because triple-negative breast cancer cells lack standard hormone receptors and high HER2 levels, traditional targeted therapies used for other breast cancer types remain ineffective. The reliance on chemotherapy historically resulted in limited durability of response, making the integration of immunotherapy a notable shift in clinical management, according to reviews published in Nature Medicine.
Managing Treatment-Related Adverse Events
Combining pembrolizumab with chemotherapy introduces immune-mediated side effects that require careful monitoring by oncology care teams. According to safety data from the American Cancer Society, common adverse reactions include fatigue, nausea, alopecia, diarrhea, and neutropenia. Immune-related adverse events can affect organs such as the lungs, colon, liver, and endocrine glands due to heightened immune system activity.
Clinical protocols require oncologists to evaluate patients regularly for signs of pneumonitis, colitis, hepatitis, and endocrinopathies. Early identification and management using corticosteroids or hormone replacement therapy allow patients to manage toxicities while continuing necessary oncological care, as outlined in treatment guidelines maintained by the National Comprehensive Cancer Network.
Worth a look